Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Othman

Showing results (391-400 of 477) with videos related to

Pageof 48
Sort By:
Diabetologia|November 30, 2011
Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?A Othman, M F Rütti, D Ernst, et al.
Plos One|May 5, 2017
Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitusJ Mwinyi, A Boström, I Fehrer, et al.
Neurosurgical Focus|September 2, 2020
Does interbody cage lordosis impact actual segmental lordosis achieved in minimally invasive lumbar spine fusion?Francis C Lovecchio, Avani S Vaishnav, Michael E Steinhaus, et al.
Clinical and Translational Science|August 22, 2024
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participantsAnees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 23, 2009
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogenZeynep S Teksin, Insong J Lee, Noble N Nemieboka, et al.
Biological Trace Element Research|February 23, 2026
Heavy Metal Air Pollution: Human Health Effects and Nanomaterial Strategies for Monitoring and RemediationYosri A Fahim, Haneen M Boughdady, Walid A Othman, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialGerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
Frontiers in Oral Health|December 15, 2025
Oral health effects of tobacco and e-cigarettes in MadinahAhmed M Kabli, Rawan K Kamal, Ahmad A Othman, et al.
Advanced Healthcare Materials|June 9, 2016
Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016)Basmah A Othman, Christina Greenwood, Ayman F Abuelela, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid ArthritisRoy M Fleischmann, Frank Wagner, Alan J Kivitz, et al.
Pageof 48

Showing results (391-400 of 477) with videos related to

Sort By:
Pageof 48
Diabetologia|November 30, 2011
Plasma deoxysphingolipids: a novel class of biomarkers for the metabolic syndrome?A Othman, M F Rütti, D Ernst, et al.
Plos One|May 5, 2017
Plasma 1-deoxysphingolipids are early predictors of incident type 2 diabetes mellitusJ Mwinyi, A Boström, I Fehrer, et al.
Neurosurgical Focus|September 2, 2020
Does interbody cage lordosis impact actual segmental lordosis achieved in minimally invasive lumbar spine fusion?Francis C Lovecchio, Avani S Vaishnav, Michael E Steinhaus, et al.
Clinical and Translational Science|August 22, 2024
Pharmacokinetics, pharmacodynamics, and safety of GS-3583, a FLT3 agonist Fc fusion protein, from single-ascending-dose phase I study in healthy participantsAnees M Dauki, Nishanthan Rajakumaraswamy, Torsten Trowe, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|May 23, 2009
Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogenZeynep S Teksin, Insong J Lee, Noble N Nemieboka, et al.
Biological Trace Element Research|February 23, 2026
Heavy Metal Air Pollution: Human Health Effects and Nanomaterial Strategies for Monitoring and RemediationYosri A Fahim, Haneen M Boughdady, Walid A Othman, et al.
Lancet (London, England)|June 18, 2018
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trialGerd R Burmester, Joel M Kremer, Filip Van den Bosch, et al.
Frontiers in Oral Health|December 15, 2025
Oral health effects of tobacco and e-cigarettes in MadinahAhmed M Kabli, Rawan K Kamal, Ahmad A Othman, et al.
Advanced Healthcare Materials|June 9, 2016
Targeted Cancer Therapy: Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity (Adv. Healthcare Mater. 11/2016)Basmah A Othman, Christina Greenwood, Ayman F Abuelela, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid ArthritisRoy M Fleischmann, Frank Wagner, Alan J Kivitz, et al.
Pageof 48